Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis
Shots:
- The US FDA has approved Ebglyss to treat moderate-to-severe AD in adults & children (≥12yrs.) weighing 88 pounds (40kg). Lilly holds its exclusive rights outside the EU, while Almirall has licensed rights in the EU
- The approval was supported by P-III (ADvocate 1 & 2) studies of Ebglyss alone and P-III (ADhere) study of Ebglyss + topical corticosteroids in over 1000 adults & children (12-18yrs.) with mod. to sev. AD
- ADvocate 1 & 2 studies showed clear or almost-clear skin in 38% vs 12% (77% maintained it for 1yr. with QM dosing & 48% maintained it after switching to PBO) and 43% vs 12% had itch relief at 16wks. (85% maintained for 1yr. with QM dosing & 66% maintained it post switching to PBO)
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Almirall Received EC’s Approval for Ebglyss (lebrikizumab) to Treat Moderate-to-severe Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
